Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea flag South Korea · Delayed Price · Currency is KRW
23,950
-1,150 (-4.58%)
At close: Mar 20, 2026

Onconic Therapeutics Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
53,39214,83821,0569560
Revenue Growth (YoY)
259.82%-29.53%22064.25%58.33%-
Cost of Revenue
10.963.7818,82514,9338,402
Gross Profit
53,38114,8352,231-14,838-8,342
Selling, General & Admin
30,3708,087---
Research & Development
9,72110,929---
Amortization of Goodwill & Intangibles
1.181.18---
Other Operating Expenses
142.77164.15---
Operating Expenses
40,76219,632---
Operating Income
12,619-4,7982,231-14,838-8,342
Interest Expense
-11.68-664.16-2,522-1,078-6,831
Interest & Investment Income
1,387942.63938.611,43118.85
Currency Exchange Gain (Loss)
-282.812,020---
Other Non Operating Income (Expenses)
1.65-7,44214.7252.865.74
EBT Excluding Unusual Items
13,713-9,942661.8-14,432-15,149
Gain (Loss) on Sale of Investments
10.77----
Pretax Income
13,724-9,942661.8-14,432-15,149
Income Tax Expense
-2,060-1,849-1,021--
Net Income
15,784-8,0931,682-14,432-15,149
Net Income to Common
15,784-8,0931,682-14,432-15,149
Shares Outstanding (Basic)
-33232323
Shares Outstanding (Diluted)
-33232323
Shares Change (YoY)
-41.46%-0.00%0.94%-
EPS (Basic)
--247.4572.78-624.23-661.40
EPS (Diluted)
--247.4572.78-624.23-661.40
Free Cash Flow
11,092-7,9822,988-17,536-8,861
Free Cash Flow Per Share
--244.07129.24-758.49-386.90
Gross Margin
99.98%99.98%10.60%--
Operating Margin
23.64%-32.33%10.60%-15618.48%-13903.24%
Profit Margin
29.56%-54.54%7.99%-15191.48%-25247.72%
Free Cash Flow Margin
20.77%-53.79%14.19%-18458.96%-14769.11%
EBITDA
13,148-4,3452,541-14,770-8,292
EBITDA Margin
24.63%-29.28%12.07%--
D&A For EBITDA
528.44452.67309.7767.4349.65
EBIT
12,619-4,7982,231-14,838-8,342
EBIT Margin
23.64%-32.33%10.60%--
Source: S&P Global Market Intelligence. Standard template. Financial Sources.